597563-62-7

Upstream product

• 342600-78-6 (S)-1-((2S,4R)-4-Benzyl-5-oxo-tetrahydro-furan-2-ylmethyl)-4-[1-methyl-1-(5-pyridin-4-yl-furan-2-yl)-ethyl]-piperazine-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide 
• 342600-76-4 (S)-4-[Cyano-methyl-(5-pyridin-4-yl-furan-2-yl)-methyl]-2-(2,2,2-trifluoro-ethylcarbamoyl)-piperazine-1-carboxylic acid allyl ester 
• 342600-77-5 (S)-4-[Cyano-methyl-(5-pyridin-4-yl-furan-2-yl)-methyl]-piperazine-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide 
• 597563-59-2 (S)-4-[1-Methyl-1-(5-pyridin-4-yl-furan-2-yl)-ethyl]-piperazine-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide 
• 1120-87-2 4-bromopyridin 

Downstream Products

• 342600-79-7 (S)-1-[(2S,4R)-2-(tert-Butyl-dimethyl-silanyloxy)-4-((3S,4S)-3-hydroxy-chroman-4-ylcarbamoyl)-5-phenyl-pentyl]-4-[1-methyl-1-(5-pyridin-4-yl-furan-2-yl)-ethyl]-piperazine-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide 

Relevant academic research and scientific papers

HIV protease inhibitors with picomolar potency against PI-resistant HIV-1 by extension of the P3 substituent

A biaryl pyridylfuran P3 substituent on the hydroxyethylene isostere scaffold affords HIV protease inhibitors (PI's) with picomolar (IC50) potency against the protease enzymes from PI-resistant HIV-1 strains. Inclusion of a gem-dimethyl substituent afforded compound 3 with 100% oral bioavailability (dogs) and more than double the t1/2 of indinavir. Inhibition of multiple P450 isoforms is dependent on the regiochemistry of the pyridyl nitrogen in these compounds.